Ovid gets in on development and commercialization of Takeda's pediatric epilepsy therapy; Deal concluded and new agreement signed
Executive Summary
Continuing with a busy deal-making month, Takeda Pharmaceutical Co. Ltd. penned an agreement with Ovid Therapeutics Inc. for development and commercialization of Takeda’s TAK935 for rare pediatric epilepsies.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice